Trump Pressures DOJ Over Delayed Cannabis Rescheduling Implementation
President expresses frustration with Justice Department's pace on marijuana policy reform four months after executive directive
President Trump publicly criticized the Department of Justice for what he termed "slow-walking" the marijuana rescheduling process, marking a notable escalation in tensions over cannabis policy implementation. The comments come four months after Trump issued an executive order directing federal agencies to expedite the rescheduling review, suggesting internal resistance or bureaucratic delays within the DOJ.
The presidential frustration highlights the complex regulatory machinery required to move cannabis from Schedule I to a lower classification under the Controlled Substances Act. While Trump's executive order provided political direction, the actual rescheduling process involves multiple federal agencies, extensive scientific review, and formal rulemaking procedures that typically span months or years. The DOJ's deliberate pace may reflect legal caution rather than political obstruction, given the sweeping implications for federal drug enforcement and interstate commerce.
Cannabis operators face continued uncertainty as the rescheduling timeline remains unclear, with many companies having positioned their business strategies around anticipated federal reform. Multi-state operators particularly stand to benefit from rescheduling, which would eliminate the punitive 280E tax provision that prevents cannabis businesses from deducting standard business expenses. This tax burden currently forces operators to pay effective rates exceeding 70% in some cases, significantly constraining profitability and expansion capital.
Trump's public pressure on the DOJ signals his administration's commitment to cannabis reform despite bureaucratic resistance. However, the president's complaints also underscore the limited executive power over entrenched federal drug policy infrastructure. The rescheduling process requires coordination between the DEA, FDA, and other agencies, each with distinct institutional cultures and regulatory priorities that may conflict with rapid policy changes.
The ongoing delay creates a challenging environment for cannabis investors and operators who anticipated quicker federal action. While Trump's vocal support for rescheduling provides political momentum, the practical timeline for implementation appears longer than initially expected. This regulatory uncertainty continues to weigh on cannabis valuations, as investors balance the potential for transformative federal reform against the reality of slow-moving government processes.